



## Notice of Results

February 2, 2023 7:00 AM EST

RNS Number : 71530  
MaxCyte, Inc.  
02 February 2023

## MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences

ROCKVILLE, MD, February 2, 2023 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative cell-based research, today announced that it will release financial results for the fourth quarter and full year 2022 after the U.S. market close on Wednesday, March 15<sup>th</sup>, 2023. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

### Earnings Conference Call Details

Investors interested in listening to the conference call are required to [register online](#). It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the "Events" section of the MaxCyte website at <https://investors.maxcyte.com/>.

Company management will also participate in the following investor conferences:

- BIO CEO & Investor Conference  
Tuesday, February 7<sup>th</sup> at 3:15 p.m. Eastern Time
- BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference  
Tuesday, February 14<sup>th</sup>
- 43<sup>rd</sup> Annual Cowen Healthcare Conference  
Tuesday, March 7<sup>th</sup> at 11:10 a.m. Eastern Time

A live and archived webcast of the Cowen presentation will be available on the "Events" section of the MaxCyte investor relations website at <https://investors.maxcyte.com/>.

### About MaxCyte

MaxCyte is a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation<sup>®</sup> platform, which facilitates complex engineering of a wide variety of cells. Our EXPERT<sup>™</sup> platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The EXPERT family of products includes: four instruments, the ATx<sup>™</sup>, STx<sup>™</sup>, GTx<sup>™</sup> and VLx<sup>™</sup>; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

### MaxCyte Contacts:

**US IR Adviser**  
**Gilmartin Group**  
David Deuchler, CFA  
+1 415-937-5400  
[ir@maxcyte.com](mailto:ir@maxcyte.com)

***Nominated Adviser and Joint Corporate Broker***

***Panmure Gordon***

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

***UK IR Adviser***

***Consilium Strategic Communications***

Mary-Jane Elliott / Chris Welsh

+44 (0)203 709 5700

[maxcyte@consilium-comms.com](mailto:maxcyte@consilium-comms.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lse.com](mailto:rns@lse.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORTTMFTMTIMMTJ